Prophylaxis against Pneumocystis jirovecii pneumonia in patients with adult T-cell lymphoma/leukemia receiving anti-CC chemokine receptor 4 monoclonal antibody.
Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan. Electronic address: yamas009@kyumed.jp.
Satoshi
S
Yamasaki
Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Kentaro
K
Kohno
Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Masanori
M
Kadowaki
Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Ken
K
Takase
Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Seiichi
S
Okamura
D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000150:complications / Q000188:drug therapy*; D008297:Male; D045363:Pneumocystis carinii; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy / Q000517:prevention & control*; D054398:Receptors, CCR4 / Q000276:immunology; D012189:Retrospective Studies; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*
D061067:Antibodies, Monoclonal, Humanized; D000935:Antifungal Agents; D054398:Receptors, CCR4; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; C549035:mogamulizumab